Last issue we flagged a slice of our weight-management cohort — maybe 10 to 20% — where tirzepatide's ceiling isn't appetite or glycemia but residual liver fat, a stubborn atherogenic lipid signal, and high-BMI cardiometabolic risk. The phenotype where the third receptor, glucagon, might move the needle. We said we'd watch the TRIUMPH readouts.

The big one just landed. TRIUMPH-1 — the pivotal general-obesity trial — reported topline results in late May. The number that caught our eye wasn't the headline. It was the extension: the heaviest patients (BMI 35+) who stayed on the top dose lost about 85 pounds over two years. That maps almost exactly onto the subset we'd flagged, so we re-read the list against the new numbers. The thesis held.

Two things to keep straight. Retatrutide is still investigational and not FDA-approved. And what we have is a company press release, not a published trial — full data presents at the major diabetes meeting on June 6, with a peer-reviewed paper to follow.

Retatrutide's pivotal obesity trial read out as strong as the headlines say — 28.3% weight loss. Here's what's real, what's still fine print, and where it fits.

The news reached most people as a single post racking up millions of views: retatrutide would "overshadow" everything before it and become the best-selling drug of all time. The numbers were real. The framing was a stock chart.

What the trial is

TRIUMPH-1 is the registrational anchor trial — roughly 2,300 adults with obesity (no diabetes), randomized to retatrutide 4, 9, or 12 mg or placebo for 80 weeks. It's the apples-to-apples comparator to the trials that launched semaglutide (STEP-1) and tirzepatide (SURMOUNT-1): the one that counts toward approval.

The numbers

Among the heaviest patients (BMI 35+) who stayed on 12 mg through 104 weeks, mean loss reached 30.3% — about 85 pounds. Nearly half of top-dose patients hit ≥30%, a threshold we used to associate with bariatric surgery. Blood pressure, triglycerides, non-HDL cholesterol, waist, and an inflammation marker (hsCRP) all moved the right way. The endpoints were pre-specified, not fished out after the fact — the magnitude is real and, for now, class-leading.

The fine print

Three things the headline skips:

- Topline, not a paper. A press release gives you the wins — not the confidence intervals, the dropouts, or the safety tables. Full data is June 6.

- The 85-pound figure is a subgroup on an extension — the heaviest patients, highest dose, two years out. The most flattering cut, not the headline result.

- "No cardiac or liver signal" is reassuring but oversold. This isn't the cardiovascular outcomes trial — that one runs through 2029 — and the two signals from our runway issue still stand: a resting heart-rate bump of 5–10 bpm, and dysesthesia (tingling, burning skin sensations) in about one in five at the top dose.

Where it fits

Retatrutide stays investigational — physician-supervised and prescription-only when it arrives, and a targeted option for a specific phenotype rather than a replacement for tirzepatide, which remains the program's workhorse. The readout firms up the case for that cohort; what it doesn't do is change access. That waits on approval and a real supply path — neither of which a topline provides.

If we've flagged you as a possible retatrutide candidate, this readout says the option is real and on track. Nothing to do today — we'll reach out if and when it becomes the right move.

Kinetic Edge Health is a physician-led telehealth practice focused on longevity, metabolic optimization, and urological wellness. If a stack in this issue is relevant to you, book a strategy session.

Short-form dispatches on longevity, metabolic health, and men’s performance — from the founder of Kinetic Edge Health.

Telehealth practice. Prescription compounds and peptides require physician evaluation. Not available in all states.

kineticedgehealth.com · Cleveland, OH

© 2026 Kinetic Edge Health, Inc. · All rights reserved.

Not for you anymore?

Use the unsubscribe link below to stop future issues.